MiNK Therapeutics Inc (INKT) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial ... [Yahoo! Finance]
MiNK Therapeutics, Inc. (INKT)
Company Research
Source: Yahoo! Finance
Net Loss (Q4 2025): $2.6 million or $0.56 per share. Net Loss (Full Year 2025): $12.5 million or $2.93 per share. Operating Cost: Decreased nearly 40% over the year. Additional Funding: Raised $3 million post-year-end through an at-the-market facility. Warning! GuruFocus has detected 8 Warning Signs with XTNT. Is INKT fairly valued? Test your thesis with our free DCF calculator. Release Date: March 31, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points MiNK Therapeutics Inc ( NASDAQ:INKT ) has advanced its allogeneic invariant natural killer T cell platform into Phase 2 clinical trials for solid tumor cancers and autoimmune inflammatory conditions, demonstrating durable survival and complete remission in heavily pretreated cancers. The company has secured external funding for trials in graft versus host disease and gastric cancer, with results expected to be presented at a major conference in th
Show less
Read more
Impact Snapshot
Event Time:
INKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INKT alerts
High impacting MiNK Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
INKT
News
- MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell TherapyGlobeNewswire
- MiNK Therapeutics (INKT) had its "buy" rating reaffirmed by HC Wainwright. They now have a $35.00 price target on the stock.MarketBeat
- MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference [TheStreet.com]TheStreet.com
- MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference [Yahoo! Finance]Yahoo! Finance
- MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International ConferenceGlobeNewswire
INKT
Earnings
- 3/31/26 - Beat
INKT
Analyst Actions
- 4/1/26 - HC Wainwright
INKT
Sec Filings
- 3/31/26 - Form 10-K
- 3/31/26 - Form 8-K
- 3/27/26 - Form 8-K
- INKT's page on the SEC website